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SIGNIFICANCE OF ERα, HER2, AND CAV1 EXPRESSION AND MOLECULAR 
SUBTYPE CLASSIFICATION TO CANINE MAMMARY GLAND TUMOR 
 
Canine mammary gland tumor and human breast cancer share many similar features 
regarding their risk factors, histopathological features, and behavior. Despite the increasing 
evidence of molecular marker expression as a prognostic factor for human breast cancer, there 
are only little studies using this approach on canine mammary gland tumor. Our aim was to 
evaluate the significance of the expression of Estrogen Receptor-alpha, Human Epidermal 
Growth Factor-2, and Caveolin-1 to the behavior and the clinical outcome of canine mammary 
gland tumor by Immunohistochemistry. We also assessed the correlation between 5 subtype 
classification (Luminal A, Luminal B, HER2-overexpressing, Basal-like, and Normal-like) and 
tumor behavior and prognosis. Canine mammary gland tissues were stained for Estrogen 
Receptor-alpha, Human Epidermal Growth Factor-2, and Caveolin-1 and evaluated for the 
positivity, and classified into 5 subtypes according to the staining status. Although there was no 
statistical significance among the subtypes, the positivity of Nuclear Estrogen Receptor-alpha, 
Extranuclear Estrogen Receptor-alpha, Human Epidermal Growth Factor-2, and Caveolin-1 
showed significant correlations (p<0.05) in the behavior and the prognosis of the tumor. This 
study indicates the prognostic value of immunohistochemistry staining status of Estrogen 
Receptor-alpha, Human Epidermal Growth Factor-2, and Caveolin-1 for canine mammary gland 
tumor. In addition, some trends were seen in 5 subtypes on the prognosis of the tumor, implying 
that although further analysis is needed, the potential application of 5 subtype classification to 
canine mammary gland tumor. 
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Canine mammary gland tumor (CMT) and human breast cancer (HBC) are both 
characterized as highly heterogeneous neoplasms regarding their clinical response and prognosis. 
Although histomorphological features are somewhat different between the two species, several 
studies using molecular markers have shown that CMT and HBC share significant similarities in 
the expression of these markers with regard to their histomorphological behavior and prognosis.12, 
29, 52, 54  
Despite attempts to investigate prognostic factors for CMT and HBC, there have been no 
definitive indicators to aide in determination of the clinical outcomes for both of these tumors. 
Recent approaches categorize HBC into 5 subtypes according to the expression of molecular 
markers have shown correlation with the behavior of the tumor.13, 18, 20, 57, 63 These markers include 
Hormone Receptors (HR), such as Estrogen Receptor-alpha (ERα) and Progesterone Receptor 
(PR), Human Epidermal Growth Factor Receptor-2 (HER2), and Basal-like markers. This 
classification system categorizes the tumor according to positive or negative expression of these 
protein molecules into Luminal A subtype (HR+, HER2-, Basal markers+/-), Luminal B subtype 
(HR+, HER2+, Basal markers+/-), HER2-overexpressing subtype (HR-, HER2+, Basal 
markers+/-), Basal-like subtype (HR-, HER2-, Basal markers+), and Normal-like subtype 
(negative for all of the markers).13, 18, 20, 57, 63 To our knowledge, there has been minimal research 
applying this classification to CMT.7, 29, 54, 54  
Previous studies evaluating the molecular expression of ERα and PR in CMT have shown 
that the behavior of these two molecules is very similar.22, 40 This can be explained by the 
expression of PR being strongly dependent on ERα.27, 40 In addition, Immunohistochemistry (IHC) 
staining of PR is less consistent when compared to that of ERα.26 In this study we used ERα as the 
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indicator for HR. ERα status has been shown to be very important in designing HBC target therapy. 
It is well known that ERα positive HBC has significantly better outcomes when treated with 
selective estrogen receptor modulators (SERM) and aromatase inhibitors.5, 19, 23, 62 The expression 
of ERα in these tumors is also related to lower grade and higher survival rates.25, 45 Hence, a major 
thrust of research, on both HBC and CMT, is to understand the relationship between ERα 
expression and tumor behavior. ERα localizes in the nucleus, plasma membrane, and cytoplasmic 
component.41 Nuclear ERα (ERαN) regulates gene transcription by two pathways. In the 
direct/classical pathway, ERαN binds to the Estrogen Responsive element in the promoter region, 
and in the indirect/non-classical pathway, it binds to non- Estrogen Responsive element region and 
regulates transcription indirectly. Extranuclear ERα (ERαC) resides in plasma membrane or 
cytoplasm. Ligand binding activates the membrane ERα, which translocates into the nucleus or 
initiates signaling cascade to activate ERαN. Cytoplasmic ERα is found in mitochondria and is 
thought to maintain the integrity of the mitochondrial membrane and prevent intrinsic cell death.42, 
64 
HER2 is a member of Human Epidermal Growth Factor Receptor family, which also 
includes HER1 (EGFR), HER3, and HER4. In physiological conditions, ligand binding initiates 
HER family dimerization. Members of the HER family form either homo- or heterodimers and 
activate signaling pathways for cell proliferation and survival. Overexpression of HER2 leads to 
excessive HER2 dimers without the presence of ligand and plays a role in the growth and 
resistance to treatment for many types of cancer.4, 35 HER2 expression has been used to predict 
prognosis and treatment sensitivity to certain cancers. In human medicine, trastuzumab, a HER2 
antagonist, has been shown to improve the prognosis significantly as a chemotherapeutic and 
adjuvant treatment agent for HER2 over-expressing metastatic HBC.20, 30, 39, 61 Thus, IHC analysis 
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of HER2 expression is used extensively in clinical and laboratory studies on HBC, and in a more 
limited basis (primarily laboratory studies) on CMT.21, 29, 30, 36, 39, 54, 61  
The term “Basal-like subtype” is implied for tumor cells expressing molecular markers 
characteristic of basal or myoepithelial cells. Thus, the Basal-like subtype is thought to be the more 
undifferentiated type of cancer, and a variety of molecular markers such as P-cadherin9, 29, 47, p6329, 
47, fatty-acid-binding protein 71, 59, EGFR3, 36, BRCA-16, 28, nestin16, 37, 43, osteonectin49, vimentin11, 
laminin38, 44, c-KIT47, and cytokeratin markers 29, 26,47, 54 are used for classification of this particular 
subtype. However, despite extensive research, the definitive molecular marker for the Basal-like 
subtype has not been agreed upon. 
Caveolins are plasma membrane proteins that control cell signaling by regulating 
membrane binding and intercellular transport of essential molecules, such as albumin, cholesterol, 
endothelial nitric oxide synthase, growth hormone, and insulin.15 Caveolin-1 (CAV1), a member of 
Caveolin family is thought to have a significant role in tumorigenesis and is highly expressed in 
myoepithelial cells, endothelial cells, and adipocytes.15, 55 Many HBC studies have found 
associations between the expression of CAV1 and Basal-like subtypes24, 25, 26  
In this study, we evaluated the significance of the IHC expression of three molecular 
markers, ERα, HER2, and CAV1 to the behavior and prognosis of CMT by two perspectives; 





MATERIALS AND METHODS 
Samples 
Tissues from 73 canine mammary gland surgical biopsies that were submitted to Colorado 
State University Veterinary Diagnostic Laboratory from 05/31/2001 to 07/30/2003 were used in 
this study. All tissues were diagnosed as CMT. Tissues were fixed in 10% buffer formalin solution, 
processed and embedded into paraffin using standard procedures, sectioned into 5μm sections 
using a Leica RM2255 rotary microtome (Leica Microsystems Inc., Buffalo Grove, IL) and 
mounted on glass slides. 
Immunohistochemistry 
5μm consecutive sections from formalin fixed paraffin embedded blocks of CMT tissues 
were tested for the presence of ERα, HER2, and CAV1 by IHC. The following primary antibodies 
were used; Monoclonal Mouse Anti-human ERα, Clone-1D5 (DAKO, Carpinteria, CA), 
Polyclonal Rabbit Anti-human HER2, C-18 (Santa Cruz Biotechnology, Dallas, TX), and 
Polyclonal Rabbit Anti-human CAV1, N-20 (Santa Cruz Biotechnology, Dallas, TX). Canine 
uterine tissue, human mammary carcinoma, and capillary endothelial cells were used as positive 
controls for ERα, HER2, and CAV1 respectively. Primary antibody incubation was omitted to 
provide a negative control for each sample. 
Immunohistochemistry for ERα  
Sections were deparaffinized and rehydrated in xylene and in descending concentrations of 
EtOH. ERα antigen was retrieved with antigen retrieval solution ph9.0 (DAKO, Carpinteria, CA) 
in a pressure cooker (Biocare Medical, Concord, CA) for 1 min. at 125ºc. Slides were cooled in 
distilled (DI) water for 1min, placed in Sequenza system (Thermo Fisher Scientific, Waltham, 
MA) and  Background sniper (Biocare Medical, Concord, CA) and hydrogen peroxide were used 
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to block nonspecific staining. Following 1:50 diluted Monoclonal Mouse Anti-Human 
ERα Clone-1D5 (DAKO, Carpinteria, CA) overnight at 4ºc, slides were incubated with EnVision+ 
Dual Link System-HRP (DAKO, Carpinteria, CA). 3’, 3’-diaminobenzidine (DAB) (Vector 
Laboratories, Burlingame, CA) was used to visualize  staining and hematoxylin was used for the 
counter-stain. Finally, slides were dehydrated with ascending concentrations of EtOH and xylene, 
mounted, and coverslipped. Slides were washed with buffered saline between procedures. All 
procedures were performed at room temperature unless indicated. 
Immunohistochemistry for HER2 and CAV1  
Sections were deparaffinized and rehydrated in xylene and in descending concentrations of 
EtOH. HER2 and CAV1 antigens were retrieved with Citra solution (Bio Genex, San Ramon, CA) 
by microwaving for 2min 30sec at 700W and then for 10min at 200W. After antigen retrieval, 
slides were cooled in DI water and placed in Hi Pro slide incubator (Thermo Fisher Scientific, 
Waltham, MA). Slides were incubated with Vector Elite diluted goat serum (Vector Laboratories, 
Burlingame, CA) and hydrogen peroxide to block background staining, then labeled with 1:500 
diluted Polyclonal Rabbit Anti-human HER-2, C-18 (Santa Cruz Biotechnology, Dallas, TX) or 
1:100 diluted Polyclonal Rabbit Anti-human CAV1, N-20 (Santa Cruz Biotechnology, Dallas, TX) 
for 15min. Following 30 min incubation with Vector Elite biotinylated anti-mouse/rabbit 
secondary antibody (Vector Laboratories, Burlingame, CA), slides were incubated with Vector 
Elite avidin biotinylated horseradish peroxidase complex (Vector Laboratories, Burlingame, CA) 
for 30min. Slides were visualized with 3-amino-9-ethyl carbazole (AEC) (Biomeda, Foster City, 
CA) and counter-stained with hematoxylin. Finally, slides were dehydrated with ascending 
concentrations of EtOH and xylene, mounted, and coverslipped. Slides were washed with buffered 
saline between procedures.  All procedures were performed at 37ºC, unless indicated.  
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Evaluation for ERα 
IHC slides were examined for ERα expression for both nuclear and extranuclear 
component. Tissues were considered positive for ERαN and/or ERαC when ≥ 5% of tumor cells 
were stained for nuclei and membrane/cytoplasm, respectively. This scoring system is the most 
commonly used method for IHC studies on CMT.45, 53, 55 The status for ERαN staining was used as 
described in the HBC 5 subtype classification.7, 13, 20, 22, 45, 48, 54, 55, 57, 63 
Evaluation for HER2 
We applied the FDA-approved scoring system for HBC, which is utilized in the HER2 
expression Hercep Test (DAKO, Carpinteria, CA) to evaluate the overexpression of HER2. The 
scoring system interprets IHC staining as HER2 positive (3+) for intense membrane staining of > 
30% of tumor cells, equivocal (2+) for complete membrane staining that is either non-uniform or 
weak in intensity but with obvious circumferential distribution in ≥ 10% of tumor cells, and 
negative (0 or 1+) for no staining or weak/incomplete membrane staining regardless of the 
distribution of stained tumor cells. In this study, we classified 3+ stained samples as positive and 
2+, 1+, and 0 samples as negative. 
Evaluation for CAV1 
Slides were evaluated for CAV1 expression using the semi-quantitative scoring system 
described previously.55 Samples were evaluated for staining intensity (0; none, 1; weakly positive, 
2; moderately positive, and 3; strongly positive) and the distribution of positively stained tumor 
cells (0; < 1%, 1; 1-9%, 2; 10-24%, 3; 25-49%, 4; 50-100%).  
The samples were considered positive if the sum of the scores for the staining intensity and 
the distribution of stained tumor cells were ≥ 4. This scoring system was described as being more 
significantly related to the survival period than methods used in other studies.51 
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5 Subtype Classifications 
All samples were classified into 5 subtypes according to the expression of three molecular 
markers; ERα, HER2, and CAV1 (Table 1). 
Table 1: 5 Subtype Classification 
 
ERαN HER2 CAV1 
Luminal A + - ± 
Luminal B + + ± 
HER2-overexpressing - + ± 
Basal-like - - + 
Normal-like - - - 
ERαN=Nuclear Estrogen Receptor-alpha, HER2=Human Epidermal Growth Factor Receptor-2, 
CAV1=Caveolin-1, ±=regardless of the positivity. 
 
History 
The primary report for each case was reviewed for sex, age at the time of surgery, and 
alteration status. In addition, a follow-up survey to assess patient prognosis was obtained from the 
referring veterinarian, which included recurrence of the tumor and the time of death. 
Histopathologic Evaluation 
Slides were stained with Hematoxylin and Eosin and evaluated for growth pattern (ductular, 
papillary, solid), invasion pattern (expansile, local, regional, nodal, vascular), percent necrosis, 
mitotic index (number of cells with mitotic figure per 10 high power fields from the neoplastic area 
with mitotic activity), degree of schirrhous reaction, degree of anaplasia, and degree of 
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inflammation (0; none, 1: mild, 2: moderate, 3: marked). 
Morphologic Classification 
The morphologic diagnosis of the CMT was derived from the classification system 
developed by Benjamin SA et al.8 The benign classification includes, adenoma simple (AdS), 
adenoma complex (AdC), benign mixed (BM), lobular hyperplasia (LH), ductular hyperplasia 
(DH), and ductular papilloma (DP). The malignant classification includes, adenocarcinoma simple 
(AS), adenocarcinoma complex (AC), ductular carcinoma (DC), and ductular papillary carcinoma 
(DPC). Tumors that were too poorly differentiated to be diagnosed morphologically were 
classified as solid carcinoma (SC). Simple adenoma/adenocarcinoma has either epithelial or 
myoepithelial component, and complex adenoma/adenocarcinoma has both epithelial and 
myoepithelial component. All samples were also classified according to their morphologic origin, 
either lobular origin or ductular origin. Lobular origin includes, AdS, AdC, BM, LH, AS, and AC. 
Ductular origin includes, DH, DP, DC, and DPC. SC was excluded from either origin.8 All 
microscopic evaluations were done by two veterinary pathologists.  
Statistical Analysis 
In this study, two different perspectives, (1) positivity of each molecular marker and (2) a 5 
subtype classification scheme, were used to analyze the correlation with the behavior and the 
prognosis of the tumors. All statistical analyses were performed using GraphPad Prism version 
4.00 (GraphPad Software, San Diego CA). To analyze the correlation with the positivity of each 
marker, Mann-Whitney test and Fisher’s exact test were used, and the correlation with the 5 
subtypes were analyzed by ANOVA (Kruskal-Wallis test) with Dunnett’s post test. The 
Kaplan-Meier survival curve with Longrank test was used to analyze the disease free interval and 





73 cases were examined for the IHC staining of three markers, ERα, HER2, and CAV1 (Fig. 
1). 35 cases (48%) were Nuclear ERαpositive (ERαN+) and 38 cases (52%) were Nuclear ERα 
negative (ERαN-). 59 cases (81%) were Extranuclear ERα positive (ERαC+) and 14 cases (19%) 
were Extranuclear ERα negative (ERαC-). 28 cases (38%) were HER2 positive (HER2+) and 45 
cases (52%) were HER2 negative (HER2-). 60 cases (82%) were CAV1 positive (CAV1+) and 13 
cases (18%) were CAV1 negative (CAV1-) (Table 2).  Extranuclear ERα staining was either 
completely positive or completely negative. 
We classified 73 cases into 5 molecular subtypes according to the expression of three 
markers; this subtype classification scheme is a modification of the published HBC scheme 13, 18, 20, 
57, 63 and used ERα markers for HR in CMT samples instead of ERα and PR used for HRs in 
evaluating HBC. 18 cases (25%) were classified as Luminal A subtype, 17 cases (23%) were 
classified as Luminal B subtype, 11 cases (15%) were classified as HER2-overexpressing subtype, 
24 cases (33%) were classified as Basal-like subtype, and 3 cases (4%) were classified as 
Normal-like subtype (Table 3). 
History 
All 73 cases were females, 21 (29%) spayed and 52 (71%) intact. There were more intact 
than spayed females regardless of molecular marker staining or tumor subtype. The age of onset 
was obtained from 67 cases. The mean age was 8.6 years old and there was no significant age 
difference between  marker positivity and among subtypes (Table 3). 
Follow-up surveys were obtained from 69 cases with the longest follow-up period of 2942 
days after diagnosis. Out of these cases, 27 cases (39%) had recurrence lesion and 31 (42%) cases 
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were deceased at the time of the report. ERαC+ tumors (44%) had significantly higher (p=0.011) 
recurrence rate than ERαC- tumors (8%), and HER2+ tumors (29%) had significantly lower 
(p=0.019) recurrence rate than HER2- tumors (43%). There were no significant differences in 
percentage of recurrence among other markers or among the subtypes. The median (50%) disease 
free interval and the median (50%) overall survival for all 69 cases were 650 days and 1333 days, 
respectively. ERαN- tumors had the shortest (584 days) and CAV1- tumors had the longest (1709 
days) median (50%) disease free interval. ERαN- tumors had the shortest (788 days) and HER2+ 
tumors had the longest (1509 days) median (50%) overall survival (Table 2). In terms of subtype, 
HER2 subtype had the lowest percentage of recurrence (18%), Basal-like subtype had the shortest 
(584 days) and Normal-like subtype had the longest (1709 days) median (50%) disease free 
interval. Normal-like subtype had the shortest (224 days) and HER2 subtype had the longest (2942 
days) median (50%) overall survival (Table 3). There were no significant differences between the 
positivity of markers among the subtypes. (Fig. 2)  
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Table 2: History and follow-up information-marker status 
 



























































































DF (day) 650 584 650 ** ** 650 650 1709 
OS (day) 1333 788 1333 ** 1509 1284 1333 1371 
* Parentheses indicate % out of total 73 cases. 
†Parentheses indicate % out of corresponding number of cases. 
¶Parentheses indicate % out of total 69 follow-up cases. 
‡Parentheses indicate % of recurrent cases out of corresponding follow-up cases. 
** Undefined data due to small number of recurrent or deceased cases. 
DF=Median Disease free interval, OS=Median Overall survival, ERαN+=Nuclear Estrogen 
Receptor-alpha positive, ERαN-=Nuclear Estrogen Receptor-alpha negative, 
ERαC+=Extranuclear Estrogen Receptor-alpha positive, ERαC-=Extranuclear Estrogen 
Receptor-alpha negative, HER2+=Human Epidermal Growth Factor Receptor-2 positive, 
HER2-=Human Epidermal Growth Factor Receptor-2 negative, CAV1+=Caveolin-1 positive, 
CAV1-=Caveolin-1 negative.  
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Table 3: History and follow-up information-subtype 
  Luminal A Luminal B  HER2 Basal Normal  Total 
Number of Cases* 18 (25%) 17 (23%) 11 (15%) 24 (33%) 3 (4%) 73 
Mean Age (year) 8.9 8.4 8.6 8.6 8.7 8.6 
Spayed† 4 (22%) 7 (41%) 4 (36%) 5 (21%) 1 (33%) 21 (29%) 
Intact†  14 (78%) 10 (59%) 7 (64%) 19 (79%) 2 (67%) 52 (71%) 
Follow-up cases¶ 18 (26%) 16 (23%) 11 (16%) 20 (29%) 2 (3%) 69 
Recurrent cases‡ 8 (44%) 6 (38%) 2 (18%) 10 (50%) 1 (50%) 27 (39%) 
DF (day) 650 ** ** 584 1709 650 
 OS (day) 1284 1485 2942 733 224 1333 
* Parentheses indicate % out of total 73 cases. 
†Parentheses indicate % out of corresponding number of cases. 
¶Parentheses indicate % out of total 69 follow-up cases. 
‡Parentheses indicate % of recurrent cases out of corresponding follow-up cases. 
** Undefined data due to small number of recurrent or deceased cases. 
DF=Median Disease free interval, OS=Median Overall survival, Luminal A=Luminal A subtype, 




Analysis of growth pattern showed the highest percentage were of the ductular pattern 
regardless of the positivity of the markers. For invasion, the expansile pattern was the most 
common pattern except for the ERαC- tumors, which did not have a distinctive dominant pattern 
(Table 3-1). Luminal A subtype (50%), Luminal B subtype (65%), HER2 subtype (46%), and 
Basal-like subtype (66%) had the ductular pattern as the highest percentage. Luminal A subtype 
(41%), Luminal B subtype (47%), and Basal-like subtype (50%) had the largest distribution of the 
expansile pattern, and HER2 subtype had  expansile (40%) and  vascular (40%) as the 
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predominant invasion patterns (Table 5). There were no significant differences in the growth and 
invasion pattern between the positivity of the markers and among the subtypes. The percent 
necrosis of ERαC+ tumors (7.7%) was significantly lower (p=0.048) than that of ERαC- tumors 
(20.6%). Degree of anaplasia was significantly lower (p=0.041) in CAV1+ tumors than CAV1- 
tumors. There were no significant differences between the positivity of markers and among the 5 
subtypes based on other histopathologic criteria.  
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Table 4: Histopathologic evaluation-marker status 
  
ERαN+ ERαN- ERαC+ ERαC- HER2+ HER2- CAV1+ CAV1- 










































































































































% Necrosis# 16.4 15.6 14.2 22.9 18.2 14.3 15.2 18.9 
Mitotic Index# 9.0 11.2 7.7 20.6 12.3 8.9 9.3 14.3 
Schirrhous Reaction# 1.5 1.6 1.6 1.4 1.6 1.4 1.5 1.8 
Anaplasia# 1.5 1.4 1.6 1.4 1.4 1.6 1.5 1.8 
Inflammation# 1.4 1.6 1.6 1.2 1.5 1.1 1.5 1.7 
* Parentheses indicate % out of total 73 cases. 
†Parenthesis indicate % out of corresponding number of cases. 
#Average. 
ERαN+=Nuclear Estrogen Receptor-alpha positive, ERαN-=Nuclear Estrogen Receptor-alpha negative, 
ERαC+=Extranuclear Estrogen Receptor-alpha positive, ERαC-=Extranuclear Estrogen Receptor-alpha 
negative, HER2+=Human Epidermal Growth Factor Receptor-2 positive, HER2-=Human Epidermal 




Table 5: Histopathologic evaluation-subtypes 
  
Luminal A Luminal B HER2 Basal Normal Total 
Number of Cases 18 (25%) 17 (23%) 11 (15%) 24 (33%) 3 (4%) 73 
Growth† 
Solid 3 (17%) 5 (29%) 3 (27%) 4 (17%) 1 (33%) 16 (22%) 
Papillary 6 (33%) 1 (6%) 3 (27%) 4 (17%) 1 (33%) 15 (21%) 
Ductular 9 (50%) 11 (65%) 5 (46%) 16 (66%) 1 (33%) 42 (57%[ 
Invasion† 
Expansile 7 (41%) 8 (47%) 4 (40%) 11 (50%) 1 (33%) 31 (45%) 
Local 4 (24%) 4 (24%) 1 (10%) 6 (27%) 0 (0%) 15 (22%) 
Regional 4 (24%) 1 (6%) 1 (10%) 3 (14%) 1 (33%) 10 (14%) 
Vascular 2 (12%) 4 (24%) 4 (40%) 2 (9%) 1 (33%) 13 (19%) 
% Necrosis# 14.7 18.2 18.2 13.8 16.7 15.8 
Mitotic Index# 8.7 9.3 16.8 5.3 38.7 10.2 
Schirrhous Reaction# 1.3 1.6 1.7 1.5 1.3 1.5 
Anaplasia# 1.4 1.6 1.7 1.3 1.7 1.5 
Inflammation# 1.6 1.3 1.6 1.6 1.7 1.5 
* Parentheses indicate % out of total 73 cases. 
†Parenthesis indicate % out of corresponding number of cases. 
#Average. 






Adenocarcinoma Simple was the most common morphological type among the 73 samples. 
There were significant differences in the trend of morphological pattern for  positivity of ERαN 
(p<0.001) and ERαC (p<0.0001) (Table 6, Fig. 3). ERαN+ had higher distribution of AdC, DPC, 
and SC, where ERαN- had higher distribution of LH, AS, and DC. ERαC+ had higher distribution 
of AdS, AdC, DH, DC, and DPC, and ERαC- had higher distribution of LH, DP, AS, and SC. 
There were no significant differences among subtypes regarding the morphological pattern. (Table 
7, Fig. 4) When dividing the morphological pattern into lobular origin and ductular origin, the 
lobular origin had much higher percentage overall, regardless of the markers’ positivity or 
subtypes (Table 6, Table 7, Fig. 3, Fig. 4). The distribution of benign tumor was slightly lower than 
that of malignant tumor without regards to the positivity of the markers or subtypes, though no 
statistical significant were observed (Table 6, Table 7, Fig. 3, Fig. 4).   
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Table 6: Distribution of morphological type indicated in % out of corresponding marker status 
  ERαN+ ERαN- ERαC+ ERαC- HER2+ HER2- CAV1+ CAV1- 
Number of Cases 35 38 59 14 28 45 60 13 
AdS 6% 5% 7% 0% 4% 9% 7% 0% 
AdC 17% 8% 15% 0% 14% 7% 13% 8% 
BM 17% 18% 17% 21% 25% 11% 20% 8% 
LH 0% 8% 3% 7% 4% 13% 2% 15% 
DH 3% 3% 3% 0% 0% 4% 3% 0% 
DP 0% 3% 0% 7% 0% 4% 0% 8% 
AS 20% 26% 22% 29% 25% 2% 27% 8% 
AC 11% 8% 10% 7% 7% 22% 10% 8% 
DC 3% 11% 8% 0% 4% 11% 5% 15% 
DPC 6% 3% 5% 0% 0% 9% 3% 8% 
SC 17% 8% 8% 29% 18% 7% 10% 23% 
Lobular 86% 80% 79% 90% 96% 76% 87% 60% 
Ductular 14% 20% 21% 10% 4% 24% 13% 40% 
Benign 41% 45% 46% 36% 46% 42% 45% 38% 
Malignant 59% 55% 54% 64% 54% 58% 55% 62% 
ERαN+= Nuclear Estrogen Receptor-alpha positive, ERαN-= Nuclear Estrogen Receptor-alpha 
negative, ERαC+= Extranuclear Estrogen Receptor-alpha positive, ERαC-= Extranuclear 
Estrogen Receptor-alpha negative, HER2+= Human Epidermal Growth Factor Receptor-2 
positive, HER2-= Human Epidermal Growth Factor Receptor-2 negative, CAV1+= Caveolin-1 
positive, CAV1-= Caveolin-1 negative. 
AdS= adenoma simple, AdC= adenoma complex, BM= benign mixed, LH= lobular hyperplasia, 
DH= ductular hyperplasia, DP= ductular papilloma, AS= adenocarcinoma simple, AC= 
adenocarcinoma complex, DC= ductular carcinoma, DPC= ductular papillary carcinoma, SC= 
solid carcinoma.  
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Table 7: Distribution of morphological type indicated in % out of corresponding subtype 
  Luminal A Luminal B HER2 Basal Normal  Total 
Number of Cases 18 17 11 24 3 73 
AdS 11% 0% 8% 4% 0% 4% 
AdC 11% 24% 0% 13% 0% 9% 
BM 11% 24% 25% 17% 0% 13% 
LH 0% 0% 8% 4% 33% 3% 
DH 6% 0% 0% 4% 0% 2% 
DP 0% 0% 8% 0% 0% 1% 
AS 22% 18% 33% 26% 0% 17% 
AC 11% 12% 0% 13% 0% 7% 
DC 6% 0% 8% 13% 0% 5% 
DPC 11% 0% 0% 0% 33% 3% 
SC 11% 24% 8% 4% 33% 9% 
Lobular 75% 100% 82% 82% 50% 83% 
Ductular 25% 0% 12% 18% 50% 17% 
Benign 39% 47% 45% 42% 33% 42% 
Malignant 61% 53% 55% 58% 67% 58% 
Luminal A= Luminal A subtype, Luminal B= Luminal B subtype, HER2= HER2-overexpressing 
subtype, Basal= Basal-like subtype, Normal= Normal-like subtype. 
AdS= adenoma simple, AdC= adenoma complex, BM= benign mixed, LH= lobular hyperplasia, 
DH= ductular hyperplasia, DP= ductular papilloma, AS= adenocarcinoma simple, AC= 






The distribution for positively stained tumors of ERαN (48%), HER2 (38%), and CAV1 
(82%) was consistent with previous IHC studies on CMT.2, 7, 29 Our results showed a high 
proportion of ERαC+ staining (82%). However, in our knowledge, there is no canine study 
reporting  IHC staining on ERαC. When we classified the tumors into 5 subtypes according to  
IHC staining, Basal-like subtype (24 cases, 33%) was the most common subtype, followed by 
Luminal A subtype (18 cases, 25%), Luminal B subtype (17 cases, 23%), HER2-overexpressing 
subtype (11 cases, 15%), and Normal-like subtype (3 cases, 4%). Among the few studies on CMT 
that use a subtype classification with IHC, Gama et al.29 used only ERα as the hormone receptor. 
The distribution of CMT for each subtype in their study was 44.8% Luminal A subtype, 13.5% 
Luminal B subtype, 8.3% HER2 subtype, 29.2% Basal-like subtype, and 4.2% Negative/null 
(equivalent to Normal-like, in this study).29 Compared to the Gama study, our results showed a 
lower distribution of Luminal A subtype and higher distribution of Luminal B subtype. This could 
be explained by the higher positivity of HER2 (38%) in our study compared to Gama’s study, 
which may be due to using primary antibodies from different manufacturers, though both studies 
used the same scoring system. Most of other previous studies on CMT applying the same 
classification method have a higher percentage of Luminal subtypes.7, 29, 53, 54 The factors 
contributing to the discrepancy in subtype distribution may be the different molecules used for the 
basal cell marker. “Basal-like” was named originally for HBC which indicates its transcriptome is 
similar to that of basal/myoepithelial cells.24 However, there are numbers of candidates for this 
particular subtype because of the abundance of markers for these cell type. For example in CMT 
studies, Gama et al. used P-cadherin, Sassi et al. used CK 5/6, and Beha et al. used CK 5/6, CK14, 
or p63.7, 29, 54 The lack of consistency in markers used for Basal-like subtype has been discussed 
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previously,58 but there is no set definition despite the pursuit to identify the molecule that 
represents this subtype. We used CAV1 as the marker for Basal-like subtype since it is strongly 
expressed in myoepithelial cells and epithelial cells of normal human breast tissue and canine 
mammary tissue.2, 51 Many human and canine research found that the correlation between CAV1 
expression and prognosis varies among tumor types, that is to say, CAV1 overexpression indicates 
either better or worse prognosis depending on the type of cancer.2, 51, 55 CAV1 is one of the 
components of caveolae, which is the membrane invaginations for various cell types and CAV1 
acts as an anchor for many signaling molecules and regulates important cellular signaling cascades 
that relate to cell proliferation and survival.15 Our data suggested that loss of CAV1 expression is 
significantly associated with higher degree of anaplasia. Loss of CAV1 function may lead to 
disruption of organized signaling pathway that are important in cell growth and metabolism, which 
results in loss of cellular differentiation and organization. Pireira et al. evaluated the changes in the 
IHC staining of CAV1 in cell types in CMT tissue and found that CAV1 is expressed in either 
luminal epithelial cells or myoepithelial cells depending on the malignancy of the tumor.51 We did 
not distinguish the type of cell that were stained with CAV1 in this study. However, differentiating 
cell types with CAV1 status may uncover stronger association of CMT with CAV1 expression 
and/or subtypes. Another factor that plays into the lower population of Luminal subtypes in our 
result compared to previous studies7, 29, 53, 54 may be the use of ERα as the sole marker for the HR. 
Many studies use ERα and PR expression when evaluating HR status on CMT. However, in human 
medicine, ERα is the only hormone receptor that is proven to have significant effect on clinical 
treatment and prognosis for HBC.23 Moreover, the behavior of PR is strongly dependent on ER, 
and the IHC staining status of PR is less consistent.26, 40 Hence, it is logical to use ERα as the 
indicator for the HR.  
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ERα status showed strong statistical significance to the distribution of morphological types. 
Toniti et al. stated that human, dog, and cat share the same major binding site for ERα to its 
endogenous ligands and SERM.60 The strong association between ERα and morphology may 
suggest the possibility of determining ERα status by routine microscopic diagnosis for future 
prognostic factor or treatment decision on CMT. The result of the follow-up survey revealed that 
the shortest median disease free interval and median overall survival was for tumors staining 
ERαN-. The loss of hormone dependency corresponding to unfavorable outcome in CMT has been 
described previously, as tumors without ERαN expression have a shorter disease free interval48 
and overall survival.45 The evaluation of positivity of the ERαC indicated that ERαC+ had 
significantly lower percent necrosis and significantly higher recurrence rate than ERαC-. There is 
evidence that membrane ERα interacts with transmembrane receptors, which trigger signaling 
cascade that contributes to phosphorylation of enzymes and ligand-independent activation of 
ERαN.42, 46 In addition, cytoplasmic ERα prevents intrinsic cell death that is initiated by 
mitochondrial disruption.42 Thus, it can be predicted that presence of ERαC contributes to the 
integrity of tumor cells. In other words, over expression of this marker might lead to higher 
susceptibility and loss of control of the cell cycle, perhaps leading to a higher recurrence rate. The 
importance ERαC function in HBC is attracting more attention in human research, but the results 
are controversial.31, 42, 50  
Recent studies have shown that membrane ERα may set in caveolae, and therefore function 
of ERα might be related to CAV1 activity.10, 14 Nevertheless, there is no research on CMT 
regarding the relationship between ERα and CAV1 nor the cross talk between ERαN and ERαC. 
Our result did not show correlation between the expression of these markers, but revealing the 




The recurrence rate for HER2+ tumor was significantly lower than HER2- tumor. In 
addition, HER2-overexpressing subtype had the lowest recurrence rate (18%) than any other 
subtypes (Luminal A; 44%, Luminal B; 38%, Basal-like; 50%, Normal-like; 50%). These results 
contradict HBC research, where HER2 overexpressing HBC has a poor prognosis, including 
higher recurrence rates.56 However, IHC studies on CMT revealed HER2 expression was 
associated with a better prognosis. 28, 34 This disparity leads to the possibility of different roles for 
HER2 between HBC and CMT.  
Although some trends were seen, current data was not statistically strong enough to 
support the correlation between the 5 subtypes and behavior or prognosis of CMT. However, there 
are still needs for further assessment of the expression of three markers in association with CMT. 
Finally, some contradicting results between HBC and CMT lead us to postulate careful 
interpretation of CMT research when used as a model for HBC, though these two species share 





Fig. 1: Immunohistochemistry staining status of CMT.  
Bar = 50μm. (A) ERαN+, ERαC+, (B) ERαN+, ERαC-, (C) ERαN-, ERαC+, (D) ERαN-, ERαC-, 




Fig. 2: Disease free interval and Overall survival.  
(A)-(E) Disease free intervals. (A) ERαN, (B) ERα, (C) HER2, (D) CAV1, (E) 5 subtypes.  




Fig. 3: Morphological evaluation according to molecular marker expression 
(A)-(D) Distribution of morphological classification. (A) ERαN, (B) ERα, (C) HER2, (D) CAV1. 





Fig. 4: Morphological evaluation according to 5 subtypes 
(A)-(F) Distribution of morphological classification. (A) Luminal A subtype, (B) Luminal B 
subtype, (C) HER2-overexpressing subtype, (D) Basal-like subtype, (E) Normal-like subtype,  
(F) Total.                    
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